AUXI SRL
4.1 FTEAUXI reported total assets of €1.20m at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Jul 2026), with 4.1 full-time equivalents.
The score of AUXI shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +71 % Total assets +110 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
AUXI's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Jul 2026
- Year ended 31 Dec 2024filed on 29 Jul 2025
- Year ended 31 Dec 2023filed on 21 Aug 2024
- Year ended 31 Dec 2022filed on 30 Aug 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
AUXI's financial analysis
- Solvency20.1%sector median: 32.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of AUXI
AUXI's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0448.506.521
- VAT number
- BE0448506521
- Peppol
- Registered · 0208:0448506521 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 14 Oct 1992
- Registered office
- 1040 Etterbeek
- Size
- Micro · 4.1 FTE
- Latest accounts
- 2025 · filed on 31 Jul 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
AUXI (SRL) has been based in Etterbeek since 1992, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 70,651 € and equity of 241,709 €; its revenue is not published. With 4.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 20.1%, below the median of its sector (32.3%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to AUXI
Companies in the same business, of comparable size and area, outside its group.
- Biocon Biologics Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €1.09m
- Wolf-Safco Wholesale of pharmaceutical and medical goods Overijse · balance sheet €1.25m
- Epredia Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €1.24m
- MiniMed Belgium Wholesale of pharmaceutical and medical goods Brussels · balance sheet 8,076 €
- Laerdal Benelux Wholesale of pharmaceutical and medical goods Vilvoorde · balance sheet €1.21m
- Thread & Lift Wholesale of pharmaceutical and medical goods Woluwe-Saint-Lambert · balance sheet €1.24m
- Mediso Medical Imaging Systems Belgium Wholesale of pharmaceutical and medical goods Auderghem · balance sheet €1.34m
- Endoceutics Wholesale of pharmaceutical and medical goods Brussels · balance sheet €3.45m
Frequently asked questions about AUXI
What is the revenue of AUXI?
AUXI files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of AUXI?
In Belgium, the VAT number is the company number prefixed with BE: BE0448506521 for AUXI, if the company is VAT-registered. Its company number (CBE) is 0448.506.521.
Where is the registered office of AUXI?
According to the CBE register, the registered office of AUXI is in 1040 Etterbeek.
What is the equity of AUXI?
At the close of the 2025 financial year, the equity of AUXI amounts to 241,709 €, a solvency of 20.1% of total assets.
How many people work at AUXI?
4.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages AUXI?
The register lists 1 active mandates at AUXI. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of AUXI
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →